ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) vs. nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

February 1, 2023

Integrity CE

M. Pishvaian

2024 ASCO® Annual Meeting Insights Hub

Integrity CE

2024 ESMO Annual Meeting Insights Hub

ASCO GI 2023 Conference Coverage

N. Uboha, A. Turk, K. Spencer, M. Cecchini

Yale Cancer Center

ASCO GI 2023 Conference Coverage

R. Kim, R. Mehta

Insights from 2023 ASCO® Annual Meeting

Y. Janjigian, S. Cytryn, S. Maron

Integrity CE

2024 ASCO® Annual Meeting Insights Hub

Yale Cancer Center

2024 ASCO® Annual Meeting Insights Hub

Hani Babiker

Yale Cancer Center

Integrity CE

J. Hernandez

Insights from 2024 ESMO GI Annual Meeting

T. Seufferlein

Total Health

Login

Login

Join VuMedi

ASCO GI 2023 NAPOLI-3 Randomized, Open-Label Phase 3 Study: Liposomal Irinotecan + 5-Fluorouracil/Leucovorin + Oxaliplatin (NALIRIFOX) vs. nab-Paclitaxel + Gemcitabine in Treatment-Naïve Patients With mPDAC

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Recommended

How Recent Data Impacts Pancreatic Cancer Management

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

ESMO 2024 Summary: Updates in Pancreatic Cancer and Impacts on Pract…

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

NORPACT-1 Trial Updates: Neoadjuvant FOLFIRINOX vs. Upfront Surgery …

Updates in Perioperative Therapy of Pancreatic Cancer

ASCO GI 2023 Key Studies

ASCO® 2023 Summary: "GI Expert Panel Discussion on Key Trials Includ…

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

GI Oncology Year in Review: Precision Medicine Update in Metastatic …

ASCO® 2024 Insights: "EXPEL-PANC - A Ph2 Study of BXCL701 + Pembro i…

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

Clinical Takeaways in From Recent Key Trials in Pancreatic Cancer

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 …

Updates in Nonmetastatic Upper-GI Adenocarcinoma

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

Updates on Pancreatic Cancer - 2023 ASCO® Direct Philadelphia